Aptar has a narrow economic moat, with durable switching costs in the Pharma business supported by intangible assets throughout the product portfolio from expertise in product regulation, design, and ...

Nerandomilast is posed to be Boehringer Ingelheim’s successor to its blockbuster Ofev (nintedanib)in IPF and PPF.

Researchers at Rice University have developed a new method for performing chemical reactions using water instead of toxic ...

Controversy surrounded Hims & Hers’ commercial, called ‘Sick of the System’, in the lead up to America’s biggest sporting ...

The number of clinical trials in which AI designed or repurposed molecules, or targeted diseases, has more than doubled since ...

His research explores the rise of generative AI and accelerated use of AI more broadly to advance drug and scientific discovery. Reuben leads Gartner's coverage of genomics, multiomics, cell and gene ...

Registration is open for faculty to attend the Westwood Lecture Series on Feb. 19. Two leading Purdue researchers will discuss the university’s growing role in the next revolution of ...

Amid the federal funding uncertainty for health and sciences, local life science leaders say this could be a moment for industry partners, investors and others to step up and support the sector.

Aims to revolutionize pharmaceutical manufacturing with focus on advanced aseptic processing technology.

“So, we need to increase efficiency on the process development side. While automation is one way of doing that, a much more efficient solution is to use in silico process development data to increase ...

The company started the first phrase of its operation in the city in January at the David Lust Accelerator Building on the Elevate Rapid City campus.

Teva Pharmaceutical’s Copaxone was approved by the FDA in 1996 to treat relapsing forms of MS, an autoimmune disorder that affects the central nervous system. Glatopa, a generic version of Teva’s ...